miR-27b-3p inhibited malignant progression capacity by targeting RUNX1, Nrf2, and MARCH7 in gastric cancer, esophageal squamous cell carcinoma, and endometrial cancer, respectively [25–27]. This evidence concerns the gene MARCHF7 and endometrial cancer.